{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:31:29Z","timestamp":1787232689303,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: U.S. mortality trends involving pancreatic cancer and pulmonary embolism (PE) and whether PE is becoming increasingly represented among pancreatic cancer deaths remain incompletely characterized. Methods: We analyzed CDC WONDER Multiple Cause of Death data for adults aged \u2265 25 years from 1999 through 2024. Deaths were included in the primary analysis when pancreatic cancer and PE were both recorded as underlying or contributing causes. Age-adjusted mortality rates (AAMRs) were evaluated using Joinpoint Regression Program version 6.0.1. Forecasting and additional weighted log-linear and segmented regression analyses were performed in R version 4.5. Additional analyses evaluated race\/ethnicity, the proportion of pancreatic cancer underlying-cause deaths with PE recorded, and sensitivity to the COVID-19 years. Results: Overall, 18,243 deaths involved both pancreatic cancer and PE. The AAMR increased from 0.19 per 100,000 in 1999 to 0.55 in 2024. Mortality increased by 2.65% annually during 1999\u20132016 and by 8.54% annually during 2016\u20132024, with a significantly steeper post-2016 slope (p &lt; 0.001). Rates were consistently higher among males and non-Hispanic Black individuals. Hispanic or Latino mortality increased significantly during 2011\u20132024, whereas estimates for Asian or Pacific Islander individuals were too sparse or frequently suppressed to support reliable longitudinal trend analysis. Among deaths with pancreatic cancer as the underlying cause, the proportion with PE recorded increased from 1.00% in 1999 to 2.85% in 2024, with significantly faster growth after 2016 (p &lt; 0.001). Excluding 2020\u20132021 did not materially alter the post-2016 increase. Conclusions: Mortality involving pancreatic cancer and PE increased substantially in the United States, and PE was recorded in a growing proportion of pancreatic cancer deaths. These death-certificate data identify an increasing population-level burden but cannot establish causality or demonstrate the effectiveness of specific clinical interventions.<\/jats:p>","DOI":"10.3390\/diseases14080303","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:57:53Z","timestamp":1787230673000},"page":"303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and Disparities in Mortality Involving Pancreatic Cancer and Pulmonary Embolism in the United States, 1999\u20132024: A CDC WONDER Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-2569","authenticated-orcid":false,"given":"Arkadeep","family":"Dhali","sequence":"first","affiliation":[{"name":"Academic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK"},{"name":"School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, Belfast BT9 7BL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmoy","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Barasat Government Medical College and Hospital, Barasat 700124, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8015-033X","authenticated-orcid":false,"given":"Ali Shan","family":"Hafeez","sequence":"additional","affiliation":[{"name":"Department of Medicine, CMH Multan Institute of Medical Sciences, Multan 60000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-9934","authenticated-orcid":false,"given":"Sajjad Ahmed","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Birat Medical College Teaching Hospital, Morang 56613, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-5295","authenticated-orcid":false,"given":"Saikat","family":"Mandal","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","first-page":"1509","article-title":"Trends in pancreatic cancer mortality in the United States 1999\u20132020: A CDC database population-based study","volume":"35","author":"Didier","year":"2024","journal-title":"Cancer Causes Control"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cgh.2019.05.059","article-title":"Racial disparities and trends in pancreatic cancer incidence and mortality in the United States","volume":"18","author":"Tavakkoli","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wu, T., Bian, Z., Qin, N., and Chen, J. (2025). Trends in pancreatic cancer mortality among US adults, 1999\u20132023. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04354-4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","article-title":"Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes","volume":"158","author":"Frere","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.pan.2019.09.002","article-title":"Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT","volume":"19","author":"Schawkat","year":"2019","journal-title":"Pancreatology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Prouse, T., Mohammad, M.A., Ghosh, S., Kumar, N., Duhaylungsod, M.L., Majumder, R., and Majumder, S. (2024). Pancreatic cancer and venous thromboembolism. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115661"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-019-0510-x","article-title":"The relationship between pancreatic cancer and hypercoagulability: A comprehensive review on epidemiological and biological issues","volume":"121","author":"Campello","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomized, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12931-025-03319-1","article-title":"Trends in pulmonary embolism mortality in cancer patients in the United States from 1999\u20132022: A CDC WONDER database study","volume":"26","author":"Dort","year":"2025","journal-title":"Respir. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Klein, R.J., and Schoenborn, C.A. (2001). Age Adjustment Using the 2000 Projected U.S. Population, Centers for Disease Control and Prevention, National Center for Health Statistics (CDC-NCHS). Healthy People 2010 Statistical Notes, Number 20.","DOI":"10.1037\/e583772012-001"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v027.i03","article-title":"Automatic time series forecasting: The forecast package for R","volume":"27","author":"Hyndman","year":"2008","journal-title":"J. Stat. Softw."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/biomet\/76.2.297","article-title":"Regression and time series model selection in small samples","volume":"76","author":"Hurvich","year":"1989","journal-title":"Biometrika"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular-weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/CCI.20.00134","article-title":"Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors","volume":"4","author":"Patt","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer\u2014A cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejca.2005.09.013","article-title":"High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients","volume":"42","author":"Blom","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/a-1548-4847","article-title":"Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine\/nab-paclitaxel","volume":"122","author":"Riedl","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/ATVBAHA.121.316463","article-title":"Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer","volume":"41","author":"Moik","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/jth.15818","article-title":"Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population","volume":"20","author":"Raskob","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ajr.12200","article-title":"Geographic disparities in pancreatic cancer survival in a southeastern safety-net academic medical center","volume":"24","author":"Markossian","year":"2016","journal-title":"Aust. J. Rural. Health"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:16:05Z","timestamp":1787231765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diseases14080303"],"URL":"https:\/\/doi.org\/10.3390\/diseases14080303","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}